Tue. 14 May 2024, 3:38am ET
Benzinga
News
- Almost half a million people diagnosed each year across the globe —
- Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED's surufatinib and anti-PD-1 activity with Hengrui's camrelizumab, promoting the immune response against tumor cells —